Sign In
Buy LPCN
$2.19
-0.0600 (-2.67%)
At Close: Jun 03, 2026
Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting
08:00am, Tuesday, 19'th May 2026
SALT LAKE CITY, May 19, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral del
BASEL, Switzerland, May 19, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage biotechnology company pioneering precision biologics to reprogram the immune system for the treatment of autoimmune and infla
Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase
08:00am, Monday, 18'th May 2026
SALT LAKE CITY, May 18, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral del
Lipocine (LPCN) Reports Q1 Loss, Beats Revenue Estimates
04:16pm, Thursday, 07'th May 2026
Lipocine (LPCN) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.35 per share a year ago.
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026
04:05pm, Thursday, 07'th May 2026
SALT LAKE CITY, May 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral del
Mangoceuticals (NASDAQ:MGRX) versus Lipocine (NASDAQ:LPCN) Financial Contrast
03:07am, Sunday, 26'th Apr 2026
Mangoceuticals (NASDAQ: MGRX - Get Free Report) and Lipocine (NASDAQ: LPCN - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies ba
John Higuchi Buys 40,000 Shares of Lipocine (NASDAQ:LPCN) Stock
05:26am, Thursday, 09'th Apr 2026
Lipocine Inc. (NASDAQ: LPCN - Get Free Report) Director John Higuchi acquired 40,000 shares of the company's stock in a transaction that occurred on Tuesday, April 7th. The shares were bought at an av
Lipocine (NASDAQ:LPCN) CEO Mahesh Patel Acquires 25,000 Shares of Stock
05:30am, Tuesday, 07'th Apr 2026
Lipocine Inc. (NASDAQ: LPCN - Get Free Report) CEO Mahesh Patel bought 25,000 shares of the company's stock in a transaction on Monday, April 6th. The stock was bought at an average cost of $2.03 per
What's Going On With Lipocine Stock On Monday?
09:09am, Monday, 06'th Apr 2026
On Thursday, the company said LPCN 1154 did not meet its primary endpoint in a Phase 3 trial for postpartum depression (PPD).
SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Lipocine Inc. (NASDAQ: LPCN). The investigation focuses on Lipocine's exe
Lipocine Stock Plunges After LPCN 1154 Misses Phase 3 Primary Endpoint
10:58am, Thursday, 02'nd Apr 2026
Lipocine said LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D17 total score compared to placebo at hour 60 in the overall study population, and the primary endpoint
Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression
08:00am, Thursday, 02'nd Apr 2026
In the Phase 3 study population (N=90) of patients with PPD, LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D17 total score compared to placebo at hour 60 (primary e
Lipocine Announces Financial Results for the Full Year Ended December 31, 2025
08:00am, Tuesday, 10'th Mar 2026
SALT LAKE CITY, March 10, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral d
Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock?
08:47am, Friday, 27'th Feb 2026
Lipocine (LPCN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)
08:00am, Wednesday, 18'th Feb 2026
SALT LAKE CITY, Feb. 18, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective ora
